People with diabetes regularly receiving dulaglutide

Description

This indicator shows the number and percent of people with diabetes receiving dulaglutide regularly. Regular use was defined as dulaglutide dispensed in three or more quarters in a year.

Rationale

Glucagon-like peptide-1 (GLP-1) receptor agonists such as dulaglutide are available since September 2021 and fully funded for the treatment of people with poorly controlled type 2 diabetes despite treatment who are at high risk of cardiovascular disease or have renal complications. 

Understanding variation in dispensing these newer medicines is important for optimising diabetes care and ensuring that patients receive the most appropriate treatments

Measure set
Health areas and conditions
Measure type
Count
Percent
Numerator

People with diabetes dispensed dulaglutide in three or four quarters in the relevant year.

Numerator detail

Medications: 414925 dulaglutide

Denominator

Count of distinct master NHIs identified as having diabetes as per the VDR.

Disaggregation

For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile. 

For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).

Notes

Exclusions 

  • People who died during the year
  • People not enrolled in a PHO

See technical document for details

Measure methodology last updated
June 2024
Reference period
2018-2022